Professor Georgina Long named as one of world's most highly cited researchers
4 December 2018
Melanoma Institute Australia’s Co-Medical Director Professor Georgina Long has been included in the 2018 Clarivate Analytics Highly Cited Researchers List in recognition of her global leadership in melanoma research and clinical trials.
Professor Long is one of only 12 researchers from The University of Sydney to be listed in the top one percent of researchers in their field. Professor Long was named in the Clinical Medicine category for her extensive work in melanoma research and clinical trials.
‘This is an outstanding achievement and great recognition of the global impact of Professor Long’s research, particularly in clinical trials,’ said fellow MIA Co-Medical Director Professor Richard Scolyer. ‘We are exceptionally proud to have someone of Georgina’s calibre as part of our team which is changing the face of melanoma treatment around the world.’
Now in its 5th year, the Clarivate Analytics Highly Cited Researchers List names the most influential researchers impacting their chosen fields, measured by rate of citation by their peers. Other researchers on the list include one of this year’s Nobel Laureates in Physiology or Medicine, Professor James P. Allison.
The Academic Ranking of World Universities uses the Highly Cited Researchers List to calculate the Highly Cited Score, which contributes to an institutions overall rank. This year, The University of Sydney climbed 15 places to its highest rank so far, due in no small part to research output of Professor Long and the other 11 researchers.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.